

### Limited Use & License Disclosure

# BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.

- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed.

  "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may
  require a separate license and additional fees. Please contact <u>order.cn@acrobiosystems.com</u> for
  further details.



# Raji/Human CD155 Stable Cell Line


Catalog No.	Size
SCRAJ-STT076	$2 \times (1 \text{ vial contains } \sim 5 \times 10^6 \text{ cells})$

### • Description

The Raji/Human CD155 Stable Cell Line was engineered to express full length human CD155 (Uniprot: P15151-1), used to mimic cancer target cells. When co-cultured with human TIGIT Reporter Cell, the TIGIT/CD155 interaction inhibits TCR signaling and NFAT-mediated luminescence. Blocking the TIGIT/CD155 interaction by either anti-TIGIT or anti-CD155 antibodies releases the inhibitory signal and results in TCR activation and NFAT-mediated luminescence.

### • Application

- Useful for cell-based CD155 binding assay
- Useful as CD155-expressing target cells in reporter gene assay





### • Cell Line Profile

Cell line	Raji/Human CD155 Stable Cell Line
Host Cell	Raji
Property	Suspension
Complete Growth Medium	RPMI-1640 + 10% FBS
Selection Marker	Hygromycin B (20 μg/mL)
Incubation	37°C with 5% CO <sub>2</sub>
Doubling Time	16-20 hours
Transduction Technique	Lentivirus

### • Materials Required for Cell Culture

- RPMI Medium 1640 (ATCC, Cat. No. 30-2001)
- Fetal bovine serum (Gibco, Cat. No. 10091-148)
- Hygromycin B (Invitrogen, Cat. No. 10687010)

**Note:** For selection antibiotics, we highly recommend using the specified brand. The activity of antibiotics may vary between manufacturers, so if you choose to use a different brand, it is essential to validate whether the concentration recommended in the culture medium is suitable. Regardless of the brand used, we recommend maintaining a backup culture without selection antibiotics to avoid potential cell loss due to inappropriate antibiotic concentration.

- Penicillin-Streptomycin (Gibco, Cat. No. 15140-122)
- Complete Growth Medium: RPMI-1640 + 10% FBS, 1%P/S
- Culture Medium: RPMI-1640 + 10% FBS, Hygromycin B (20 µg/mL), 1%P/S
- Freeze Medium: 90% FBS, 10% (V/V) DMSO
- T-75 Culture flask (Corning, Cat. No. 430641)
- Cryogenic storage vials (SARSTEDT, Cat. No. 72.379.007)
- Thermostat water bath
- Centrifuge (Cence, Model: L550)
- Cell counter (MONWEI, Model: SmartCell200A Plus)
- CO2 Incubator (Thermo, Model: 3111)
- Biological Safety Cabinet (Thermo, Model: 1389)



### • Recovery

- 1. Thaw the vial by gently agitating it in a 37°C water bath. To minimize the risk of contamination, ensure the cap remains out of the water. Thawing should be completed quickly, typically within 3-5 minutes.
- 2. After thawing, promptly remove the vial from the water bath and decontaminate it by spraying with 70% ethanol. From this point onward, all operations must be performed under strict aseptic conditions.
- 3. Transfer the contents of the vial to a centrifuge tube containing 4.0 mL of complete growth medium.
- 4. Count viable cells and centrifuge at approximately 1000 rpm for 5 minutes.
- Discard the supernatant and resuspend the cell pellet in an appropriate amount of fresh complete growth medium. Adjust the cell density of the suspension to 1×10<sup>6</sup> viable cells/mL and transfer cells to an appropriate size vessel.
- 6. Incubate at 37°C with 5% CO<sub>2</sub> incubator.

#### • Subculture

Cell viability may be low after thawing, and full recovery (viability >90%) may take up to 1-2 weeks. Once the cell density reaches approximately  $1.5\times10^6$  viable cells/mL, adjust the density to a range of  $1\times10^5$ - $2\times10^5$  viable cells/mL by either adding the fresh culture medium or replacing the existing culture medium. Avoid allowing the cell density to exceed  $2\times10^6$  cells/mL, as this may negatively impact cell performance in subsequent passages. T-75 flasks are recommended for subculturing.

• **Subculturing Frequency:** It is recommended to subculture every 3-4 days, adjusting the frequency based on the cell density in your specific culture system.

**Note:** After recovery, maintain the cells for 1-2 passages in the complete growth medium not containing the selection marker, if the cells are in good condition (viability >90%), transition to the culture medium containing the selection marker during subculturing.



### Cryopreservation

- 1. Count viable cells and harvest the cell suspension.
- 2. Centrifuge at 1000 rpm for 5 min at room temperature and resuspend cells in ice cold freezing medium to a concentration of  $5 \times 10^6$  to  $1 \times 10^7$  cells/mL.
- 3. Aliquot the cell suspension into cryogenic storage vials. Place the vials in a programmable cooler or an insulated box placed in a –80°C freezer overnight, then transfer to liquid nitrogen storage for long-term storage.


Note: It is recommended to establish a cell bank at the earliest possible passage for long-term use.

### • Storage

Cells must be received in a frozen state on dry ice and should be transferred to liquid nitrogen or a  $-80^{\circ}$ C freezer immediately upon receipt. If stored in a  $-80^{\circ}$ C freezer, it is recommended to limit the storage period to no more than two weeks. For long-term preservation, transfer the cells to liquid nitrogen is highly recommended.



#### • Receptor Assay



Catalog No.	Stable Cell Line	MFI for CD155 (PE)
NA	Negative Control Cell	113.79
SCRAJ-STT076	Raji/Human CD155 Stable Cell Line	67123.32

**Fig1. Expression analysis of human CD155 on Raji/Human CD155 Stable Cell by FACS.** Raji/Human CD155 Stable Cell Line or negative control cell were stained with PE-labeled anti-Human CD155 antibody.

## Application





Fig2. Blocking activity of anti-human TIGIT antibody. This Raji/Human CD155 Stable Cell Line was incubated with serial dilutions of antibodies in the presence of reporter cells expressing human TIGIT. The EC50 of anti-human TIGIT antibody was approximately  $2.05 \,\mu\text{g/mL}$ .



# • Passage Stability



Passage	MFI for CD155 (PE)
P5	54637
P12	57014
P18	60346
P28	55681

**Fig3. Passage stability analysis of receptors expression by FACS.** Flow cytometry surface staining of human CD155 on Raji/Human CD155 Stable Cell Line demonstrates consistent mean fluorescent intensity across passage 5-28.



### • Related Products

<u>Products</u>	Cat.No.
HEK293/Human PD-L1, GFP Tag Stable Cell Line	CHEK-ATP002
HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line	CHEK-ATP039
HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line	CHEK-ATP038
Human PD-1/LAG-3 (Luc) Jurkat Reporter	SCJUR-STF063
Human PD-1 (Luc) Jurkat Reporter Cell	SCJUR-STF064
Human LAG-3 (Luc) Jurkat Reporter Cell	SCJUR-STF065
Raji/Human PD-L1 Stable Cell Line	SCRAJ-STT075
CHO/Human LILRB4 Stable Cell Line	SCCHO-ATP087
HEK293/Human LILRB4 Stable Cell Line	CHEK-ATP088
Raji/Human HVEM Stable Cell Line	SCRAJ-STF108
CHO/Human LIGHT Stable Cell Line	SCCHO-ATP109
CHO/Human BTLA Stable Cell Line	SCCHO-ATP110
HEK293/Human PD-1 Stable Cell Line	CHEK-ATP143
HEK293/Human HVEM Stable Cell Line	CHEK-ATP147
HEK293/Human NKp46 Stable Cell Line	CHEK-ATP153
HEK293/Human ITPRIPL1 Stable Cell Line	CHEK-ATP203
Human NKp46 (Luc) Jurkat Reporter Cell	SCJUR-STF130